{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:21:05Z","timestamp":1793985665441,"version":"4.8.0"},"posted":{"date-parts":[[2026,2,4]]},"group-title":"HIV\/AIDS","reference-count":44,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>HIV-specific broadly neutralising antibodies (bNAbs) can maintain viral control after interrupting antiretroviral therapy (ART). We investigated the duration and efficacy of Fc-engineered long-acting bNAbs (LS-bNAbs) in maintaining ART-free HIV control compared with placebo.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>RIO is a 1:1 randomised double-blind placebo-controlled trial of two LS-bNAbs (3BNC117-LS &amp; 10-1074-LS) in individuals virally suppressed on ART initiated since early-stage HIV. Eligible participants interrupted ART after receiving blinded infusions of either both LS-bNAbs (Arm-A) or placebo (Arm-B). A second optional blinded infusion was offered after 20 weeks for participants who remained virally suppressed without ART. The primary outcome was time to viral rebound 20 weeks after ART interruption, defined as either the first of six consecutive plasma HIV RNA &gt;1,000 copies\/mL, or two measurements &gt;100,000 copies\/mL. Secondary outcomes included adverse events, long-term viral control and bNAb pharmacokinetics.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Findings<\/jats:title>\n                  <jats:p>Sixty-eight participants were randomised, thirty-four to each arm. By week 20, viral rebound had occurred in 8 Arm-A and 30 Arm-B participants; 75% (95% CI, 61 \u2013 92) of Arm-A participants had not rebounded, compared to 11% (95% CI, 4-29) participants in Arm-B. Arm-A participants were 91% less likely to rebound compared to Arm-B participants (hazard ratio of rebound (HR): 0.09; 95% confidence interval (CI) 0.04 \u2013 0.21, P &lt; 0.001). ART-free viral control using the above endpoints beyond 96 weeks was evident in 7 (25%, 95% CI 13 \u2013 48) Arm-A participants compared to 2 (11%, 95% CI 4 \u2013 29) Arm-B participants (HR: 0.22, 95% CI 0.12 \u2013 0.40, P &lt; 0.001). These seven participants had predicted serum bNAb concentrations below the presumed therapeutic threshold of 10 \u03bcg\/mL at 96 weeks. Of nine serious adverse events, none were study-related.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Long-acting bNAbs can sustain extended ART-free viral control in people treated during early-stage HIV and represent a promising step towards achieving ART-free HIV remission.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Funding<\/jats:title>\n                  <jats:p>\n                    The RIO trial was funded by the Bill &amp; Melinda Gates Foundation (grant ref. OPP1210792). Infrastructure support in the UK for this research was provided by the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre (BRC), the NIHR Imperial Clinical Research Facility (ICRF) and the Oxford NIHR BRC.\n                    <jats:list list-type=\"bullet\">\n                      <jats:list-item>\n                        <jats:p>Study\/trial registration numbers and date of registration:<\/jats:p>\n                        <jats:list list-type=\"simple\">\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>UK Research Ethics Committee reference: 19\/LO\/1669 (11 Sep 2019)<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>EudraCT: 2019-002129-31 (12 Dec 2019)<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>EU CTR: 2024-514564-13-00 (02 Jan 2025)<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>\n                              ClinicalTrials.gov Identifier:\n                              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04319367\">NCT04319367<\/jats:ext-link>\n                              (02 Mar 2020)\n                            <\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>UK IRAS: 266322<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>Sponsor Protocol Number: 19IC5249<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:label>\u25cb<\/jats:label>\n                            <jats:p>Funder Reference: OPP1210792<\/jats:p>\n                          <\/jats:list-item>\n                        <\/jats:list>\n                      <\/jats:list-item>\n                    <\/jats:list>\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Evidence in context<\/jats:title>\n                  <jats:p>We systematically searched Medline, Embase, and Web of Science databases until April 2024 with additional searches updated until January 2026. Combination therapy of HIV-specific broadly neutralising antibodies (bNAbs) has demonstrated periods of viral control for people living with HIV who interrupt their antiretroviral treatment. The development of long-lasting LS-bNAbs with Fc-receptor modifications has been shown to increase the serum half-lives by up to four-fold. To date, the clinical efficacy and duration of ART-free HIV control with LS-bNAbs has not been evaluated in a sufficiently powered human trial.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Added value of this study<\/jats:title>\n                  <jats:p>The RIO trial; a prospective double blind randomised controlled study for the first time demonstrates that a single dose of two bNAbs 10-1074-LS and 3BNC117-LS was 91% more effective in maintaining ART-free viral control to twenty weeks compared to placebo. The long-term follow up to 96 weeks adds new data on the duration and frequency (25%) of viral control conferred by two doses of LS-bNAbs beyond the expected frequencies of post-treatment control in an early treated cohort of people living HIV. ART-free viral control beyond 96 weeks is likely due to post-bNAb induced mechanisms as modelled bNAb concentrations past this time were below presumed therapeutic thresholds. Administration of LS-bNAbs was safe and not associated with any Severe Adverse Events.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Implications of all the available evidence<\/jats:title>\n                  <jats:p>LS-bNAbs represent a major advance towards ART-free HIV control and remission as an achievable goal. These findings will inform future combination strategies to enhance the mechanisms of post-bNAb HIV control.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.04.25342277","type":"posted-content","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T01:15:16Z","timestamp":1770254116000},"source":"Crossref","is-referenced-by-count":5,"title":["Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial"],"prefix":"10.64898","author":[{"given":"Ming Jie","family":"Lee","sequence":"first","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise-Rae","family":"Cherrill","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Zacharopoulou","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Collins","sequence":"additional","affiliation":[{"name":"HIV i-Base, London (S.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcilio","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Falaschetti","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Altaf","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Tipoe","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"},{"name":"Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong (T.T.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyumika","family":"Godakandaarachi","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas Hospital NHS Foundation Trust (P.G., J. Fox.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Fox","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas Hospital NHS Foundation Trust (P.G., J. Fox.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Uriel","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester (A.U., I.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Clarke","sequence":"additional","affiliation":[{"name":"University Hospitals Sussex NHS Foundation Trust and Brighton & Sussex Medical School (A.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine Kinloch-de","family":"Loes","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust (S.K-L.)"},{"name":"University College London (S.K-L., S.P)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Pett","sequence":"additional","affiliation":[{"name":"University College London (S.K-L., S.P)"},{"name":"Central and Northwest London NHS Foundation Trust (S.P.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, London (M.B., G.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Whitlock","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital, London (M.B., G.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Schmeltz","family":"S\u00f8gaard","sequence":"additional","affiliation":[{"name":"Aarhus University and Aarhus University Hospital, Aarhus, Denmark (O.S.S., J.D.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Ring","sequence":"additional","affiliation":[{"name":"Queen Mary University of London and Barts Health NHS Trust, London (C.O., K.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvine","family":"Mangawa","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust, Manchester (A.U., I.M.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesal","family":"Gohil","sequence":"additional","affiliation":[{"name":"Imperial College Healthcare NHS Trust, London (J.G.) \u2013 all in the United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Elliott","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) (S. Fidler., T.E., H. B.,)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Aalborg University and Aalborg University Hospital, Aalborg, Denmark (H.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper Damsgaard","family":"Gunst","sequence":"additional","affiliation":[{"name":"Aarhus University and Aarhus University Hospital, Aarhus, Denmark (O.S.S., J.D.G.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"Queen Mary University of London and Barts Health NHS Trust, London (C.O., K.R.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Western General Hospital, NHS Lothian Trust, Edinburgh (R.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hamzah","sequence":"additional","affiliation":[{"name":"St George\u2019s University Hospital, London NHS Foundation Trust (L.H)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cicconi","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"},{"name":"Centre for Clinical Vaccinology and Tropical Medicine and the Oxford University Hospitals NHS Foundation Trust (P.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham P.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie","family":"Ujetz","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishrat","family":"Jahan","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Brown","sequence":"additional","affiliation":[{"name":"National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) (S. Fidler., T.E., H. B.,)"},{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fletcher","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Box","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Seaton","sequence":"additional","affiliation":[{"name":"Duke University, Durham, USA (K.F.S., H.M.G, G.D.T)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Tomaras","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"},{"name":"Duke University, Durham, USA (K.F.S., H.M.G, G.D.T)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"},{"name":"Dartmouth College, New Hampshire, USA (M.E.A., J.A.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Weiner","sequence":"additional","affiliation":[{"name":"Dartmouth College, New Hampshire, USA (M.E.A., J.A.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kaczynska","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Bittar","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Horowitz","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Claudio","family":"Nussenzweig","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"},{"name":"Howard Hughes Medical Institute, Chevy Chase, USA (M.C.N.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Caskey","sequence":"additional","affiliation":[{"name":"The Rockefeller University, New York, USA (M.F., C.B., A.K., J.H., M.C.N., M.C.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Frater","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, the University of Oxford (P.Z., T.T., M.A., H. Brown.,N.R, P.C., J.F.)"},{"name":"National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) (J. F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Fidler","sequence":"additional","affiliation":[{"name":"Imperial College London (M.J.L., L-R.C., E.F., G. Taylor., J.U., I.J., S.F., H. B., T.E., G.T., S. Fidler.)"},{"name":"National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) (S. Fidler., T.E., H. B.,)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the RIO Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026020607051589000_2026.02.04.25342277v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00028-0"},{"key":"2026020607051589000_2026.02.04.25342277v1.2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11904-023-00653-1","article-title":"HIV Reservoir: How to Measure It?","volume":"20","year":"2023","journal-title":"Current HIV\/AIDS Reports"},{"key":"2026020607051589000_2026.02.04.25342277v1.3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/09564624231169329","article-title":"Barriers to adherence to antiretroviral therapy: identifying priority areas for people with HIV and healthcare professionals","volume":"34","year":"2023","journal-title":"Int J STD AIDS"},{"key":"2026020607051589000_2026.02.04.25342277v1.4","unstructured":"Impact of US funding cuts on the global HIV response | UNAIDS. https:\/\/www.unaids.org\/en\/impact-US-funding-cuts (accessed April 15, 2025)."},{"key":"2026020607051589000_2026.02.04.25342277v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00009-1"},{"key":"2026020607051589000_2026.02.04.25342277v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1"},{"key":"2026020607051589000_2026.02.04.25342277v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.08.003"},{"key":"2026020607051589000_2026.02.04.25342277v1.8","doi-asserted-by":"crossref","unstructured":"Julg B , Dee L , Ananworanich J , et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials\u2014report of a consensus meeting. In: The Lancet HIV. Elsevier Ltd, 2019: e259\u201368.","DOI":"10.1016\/S2352-3018(19)30052-9"},{"key":"2026020607051589000_2026.02.04.25342277v1.9","doi-asserted-by":"crossref","first-page":"105788","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","year":"2024","journal-title":"Antiviral Res"},{"key":"2026020607051589000_2026.02.04.25342277v1.10","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","article-title":"Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial","volume":"3","year":"2022","journal-title":"Lancet Microbe"},{"key":"2026020607051589000_2026.02.04.25342277v1.11","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020607051589000_2026.02.04.25342277v1.12","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411"},{"key":"2026020607051589000_2026.02.04.25342277v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268"},{"key":"2026020607051589000_2026.02.04.25342277v1.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1207227"},{"key":"2026020607051589000_2026.02.04.25342277v1.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217207109"},{"key":"2026020607051589000_2026.02.04.25342277v1.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2"},{"key":"2026020607051589000_2026.02.04.25342277v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04797-9"},{"key":"2026020607051589000_2026.02.04.25342277v1.18","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","year":"2022","journal-title":"Nature"},{"key":"2026020607051589000_2026.02.04.25342277v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0001-2"},{"key":"2026020607051589000_2026.02.04.25342277v1.20","doi-asserted-by":"publisher","DOI":"10.3390\/PHARMACEUTICS16050594"},{"key":"2026020607051589000_2026.02.04.25342277v1.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06231-x"},{"key":"2026020607051589000_2026.02.04.25342277v1.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309215110"},{"key":"2026020607051589000_2026.02.04.25342277v1.23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4"},{"key":"2026020607051589000_2026.02.04.25342277v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112764"},{"key":"2026020607051589000_2026.02.04.25342277v1.25","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12742"},{"key":"2026020607051589000_2026.02.04.25342277v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00858-w"},{"key":"2026020607051589000_2026.02.04.25342277v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02547-6"},{"key":"2026020607051589000_2026.02.04.25342277v1.28","first-page":"2025.11.03.25339415","article-title":"Enhanced HIV-1 Control After Antibody Therapy is Associated with Autologous Antibodies and Reservoir Clearance in the RIO trial","volume":"10","year":"2025","journal-title":"medRxiv"},{"key":"2026020607051589000_2026.02.04.25342277v1.29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.16.10108-10125.2005"},{"key":"2026020607051589000_2026.02.04.25342277v1.30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02660-07"},{"key":"2026020607051589000_2026.02.04.25342277v1.31","doi-asserted-by":"publisher","DOI":"10.1093\/NAR\/GKQ543"},{"key":"2026020607051589000_2026.02.04.25342277v1.32","doi-asserted-by":"publisher","DOI":"10.1038\/nature18929"},{"key":"2026020607051589000_2026.02.04.25342277v1.33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/COH.0000000000000731","article-title":"An exploration of how broadly neutralizing antibodies might induce HIV remission: the \u2018vaccinal\u2019 effect","volume":"17","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"key":"2026020607051589000_2026.02.04.25342277v1.34","doi-asserted-by":"publisher","DOI":"10.1084\/JEM.20201214"},{"key":"2026020607051589000_2026.02.04.25342277v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-34171-2"},{"key":"2026020607051589000_2026.02.04.25342277v1.36","doi-asserted-by":"crossref","unstructured":"Kiani Z , Urbach JM , Wisner H , et al. CD8+ T cell stemness precedes post-intervention control of HIV viraemia. Nature 2025 2025;: 1\u20139.","DOI":"10.1038\/s41586-025-09932-w"},{"key":"2026020607051589000_2026.02.04.25342277v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08374-0"},{"key":"2026020607051589000_2026.02.04.25342277v1.38","first-page":"26345374","article-title":"T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy","volume":"10","year":"2026","journal-title":"medRxiv"},{"key":"2026020607051589000_2026.02.04.25342277v1.39","unstructured":"Dong K , Asari V , Govender V , et al. Evaluation of 2 bNAbs Plus Vesatolimod in Early-Treated South African Women With HIV-1 During ATI. In: CROI. 2025. https:\/\/www.croiconference.org\/abstract\/2240-2025\/ (accessed April 15, 2025)."},{"key":"2026020607051589000_2026.02.04.25342277v1.40","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","article-title":"Multi-stakeholder consensus on a target product profile for an HIV cure","volume":"8","year":"2021","journal-title":"Lancet HIV"},{"key":"2026020607051589000_2026.02.04.25342277v1.41","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","article-title":"Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study","volume":"11","year":"2024","journal-title":"Lancet HIV"},{"key":"2026020607051589000_2026.02.04.25342277v1.42","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-6141479\/V1"},{"key":"2026020607051589000_2026.02.04.25342277v1.43","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002919"},{"key":"2026020607051589000_2026.02.04.25342277v1.44","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf7966"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.04.25342277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T15:05:28Z","timestamp":1770390328000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.02.04.25342277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":44,"URL":"https:\/\/doi.org\/10.64898\/2026.02.04.25342277","relation":{},"subject":[],"published":{"date-parts":[[2026,2,4]]},"subtype":"preprint"}}